HF
TRML

HRT Financial’s Tourmaline Bio TRML Stock Holding History

HRT Financial’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-26,876
Closed -$429K – 3686
2025
Q2 		$429K Buy
+26,876
New +$435K ﹤0.01% 1677
2024
Q2 		– Sell
-61,307
Closed -$1.4M – 3119
2024
Q1 		$1.4M Buy
+61,307
New +$2.16M 0.01% 723

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

HRT Financial's TRML Position: Q3 2025 in Review

HRT Financial sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 26,876 shares — an estimated $429K sold.

HRT Financial first reported a position in TRML in Q1 2024 and held it in 2 quarters. The position peaked at $1.4M in Q1 2024. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • HRT Financial reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 26,876 Tourmaline Bio shares in Q3 2025, an estimated $429K.
  • HRT Financial first reported a position in Tourmaline Bio in Q1 2024 and held it in 2 quarters.
  • HRT Financial's Tourmaline Bio position peaked at $1.4M in Q1 2024.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.